Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

CC-42344 Antiviral Activity: Cocrystal Pharma's CC-42344 has demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza strain, showing approximately 1,000-fold greater potency compared to Tamiflu, and is being developed as an oral treatment for both pandemic and seasonal influenza infections.

Concerns Over Avian Influenza Spread: The outbreak of H5N1 in dairy cows has raised concerns about potential human-to-human transmission, with low population immunity observed in the U.S., highlighting the need for effective treatments as avian flu viruses may become resistant to existing antivirals.